TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05983432: A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Sponsor: SystImmune Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 540 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,267,264

Rescue Site Savings

+$2,167,704

Unlock Full NCT05983432 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05983432 Rescue Dossier →